Tourmaline Bio Inc
TRML47.690USD
-0.010-0.02%
Close 09/18, 16:00（ET）Quotes delayed by 15 min
1.23BMarket Cap
LossP/E TTM
More Details of Tourmaline Bio Inc Company
Tourmaline Bio, Inc. is a late-stage clinical biotechnology company. The Company is focused on developing transformative medicines that improve the lives of patients with life-altering immune and inflammatory diseases. The Company’s initial product candidate is TOUR006, a fully human monoclonal antibody that selectively binds to interleukin-6 (IL-6), a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. TOUR006 is a long-acting anti-IL-6 antibody which has properties, including a high binding affinity to IL-6, long half-life, and low observed immunogenicity. It is also developing TOUR006 in thyroid eye disease (TED) and atherosclerotic cardiovascular disease (ASCVD) as its first two indications, with additional diseases under consideration. It is focused on two strategic paths for TOUR006, the first of which it refers to as FcRn+. Its second strategic path is cardiovascular inflammation.
Company Info
Ticker SymbolTRML
Company nameTourmaline Bio Inc
IPO dateMay 07, 2021
CEODr. Sandeep Kulkarni, M.D.
Number of employees74
Security typeOrdinary Share
Fiscal year-endMay 07
Address27 West 24th Street, Suite 702
CityNEW YORK
Stock exchangeNASDAQ Global Select Consolidated
CountryUnited States of America
Postal code10010
Phone
Websitehttps://www.tourmalinebio.com/
Ticker SymbolTRML
IPO dateMay 07, 2021
CEODr. Sandeep Kulkarni, M.D.
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Aaron Kantoff
Mr. Aaron Kantoff
Independent Director
Independent Director
93.28K
+105.51%
Mr. Parvinder Thiara
Mr. Parvinder Thiara
Independent Director
Independent Director
83.78K
--
Dr. Sapna Srivastava, Ph.D.
Dr. Sapna Srivastava, Ph.D.
Independent Director
Independent Director
518.00
--
Mr. Brad Middlekauff, J.D.
Mr. Brad Middlekauff, J.D.
Chief Business Officer and General Counsel
Chief Business Officer and General Counsel
--
--
Dr. Susan Dana Jones, Ph.D.
Dr. Susan Dana Jones, Ph.D.
Chief Technology Officer
Chief Technology Officer
--
--
Mr. Ryan Robinson
Mr. Ryan Robinson
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
--
--
Dr. Clay B. Siegall, Ph.D.
Dr. Clay B. Siegall, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Kevin Johnson, Ph.D.
Mr. Kevin Johnson, Ph.D.
Chief Regulatory Officer
Chief Regulatory Officer
--
--
Dr. Sandeep Kulkarni, M.D.
Dr. Sandeep Kulkarni, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Dr. Caley M. Castelein, M.D.
Dr. Caley M. Castelein, M.D.
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Aaron Kantoff
Mr. Aaron Kantoff
Independent Director
Independent Director
93.28K
+105.51%
Mr. Parvinder Thiara
Mr. Parvinder Thiara
Independent Director
Independent Director
83.78K
--
Dr. Sapna Srivastava, Ph.D.
Dr. Sapna Srivastava, Ph.D.
Independent Director
Independent Director
518.00
--
Mr. Brad Middlekauff, J.D.
Mr. Brad Middlekauff, J.D.
Chief Business Officer and General Counsel
Chief Business Officer and General Counsel
--
--
Dr. Susan Dana Jones, Ph.D.
Dr. Susan Dana Jones, Ph.D.
Chief Technology Officer
Chief Technology Officer
--
--
Mr. Ryan Robinson
Mr. Ryan Robinson
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Fri, Aug 15
Updated: Fri, Aug 15
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Avoro Capital Advisors LLC
9.92%
RA Capital Management, LP
9.86%
QVT Financial LP
8.37%
Hydra LLC
6.61%
TCG Crossover Management, LLC
5.74%
Other
59.51%
Shareholders
Shareholders
Proportion
Avoro Capital Advisors LLC
9.92%
RA Capital Management, LP
9.86%
QVT Financial LP
8.37%
Hydra LLC
6.61%
TCG Crossover Management, LLC
5.74%
Other
59.51%
Shareholder Types
Shareholders
Proportion
Investment Advisor
28.29%
Hedge Fund
24.04%
Investment Advisor/Hedge Fund
21.11%
Venture Capital
12.16%
Corporation
11.55%
Individual Investor
10.48%
Research Firm
2.65%
Bank and Trust
0.28%
Pension Fund
0.16%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
265
28.81M
112.16%
-5.65M
2025Q1
278
29.06M
113.12%
-6.65M
2024Q4
267
27.86M
108.65%
-4.54M
2024Q3
254
27.28M
106.38%
-4.78M
2024Q2
248
27.58M
107.55%
-803.47K
2024Q1
238
26.92M
105.10%
+7.92M
2023Q4
193
17.05M
91.28%
+8.99M
2023Q3
170
3.58M
159.92%
-896.76K
2023Q2
178
3.46M
81.64%
-454.91K
2023Q1
158
3.62M
86.22%
-261.50K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Avoro Capital Advisors LLC
2.42M
9.44%
+202.78K
+9.13%
Mar 31, 2025
RA Capital Management, LP
2.54M
9.88%
--
--
Mar 31, 2025
QVT Financial LP
1.47M
5.74%
+762.09K
+107.14%
Mar 31, 2025
Hydra LLC
1.70M
6.63%
+500.00K
+41.59%
Dec 31, 2023
TCG Crossover Management, LLC
1.48M
5.75%
--
--
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
1.60M
6.23%
-14.27K
-0.88%
Mar 31, 2025
Pfizer Inc
1.27M
4.95%
--
--
Mar 31, 2025
The Vanguard Group, Inc.
1.19M
4.62%
+84.69K
+7.68%
Mar 31, 2025
Blue Owl Capital Holdings LP
1.04M
4.04%
-42.21K
-3.91%
Mar 31, 2025
Castelein (Caley M.)
974.56K
3.79%
--
--
Mar 31, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Oct 19, 2023
Merger
10→1
Oct 19, 2023
Merger
10→1
Oct 19, 2023
Merger
10→1
Oct 19, 2023
Merger
10→1
Date
Type
Ratio
Oct 19, 2023
Merger
10→1
Oct 19, 2023
Merger
10→1
Oct 19, 2023
Merger
10→1
Oct 19, 2023
Merger
10→1
